Newsbenzinga
Xenon Stock Reaction Is Overblown: Analyst
· Published
Article summary
Xenon Pharmaceuticals submits an FDA application for azetukalner for seizures while voluntarily pausing enrollment in depression trials.
An excerpt from the original article.
Comments —
Loading comments…